Wedbush raised the firm’s price target on Ardelyx (ARDX) to $14 from $13 and keeps an Outperform rating on the shares. The firm notes Ardelyx posted a solid performance in Q2 with total revenue beating by $16M, driven by Ibsrela strength. Management increased the FY25 Ibsrela guidance range to $250M-$260M and Wedbush thinks this is an achievable bar. Finally, Ardelyx announced multiple leadership changes and CFO Justin Renz will exit the company in the coming months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx price target raised to $12 from $11 at Raymond James
- Ardelyx’s Strong Commercial Execution and Growth Prospects Drive Buy Rating
- Ardelyx Reports Strong Q2 2025 Financial Performance
- Ardelyx’s Strong Performance and Sales Outlook Justify Buy Rating
- Ardelyx CFOO Justin Renz to depart, John Bishop named CTOO